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A B S T R A C T
This paper addresses the modiﬁcation of poly(dimethylsiloxane), i.e. PDMS, using plasma surface treatment and
a novel application of the membrane created. A set of model compounds were analysed to determine their
permeation through PDMS, both with and without plasma treatment. It was found that plasma treatment
reduced permeation for the majority of compounds but had little eﬀect on some compounds, such as caﬀeine,
with results indicating that polarity plays an important role in permeation, as is seen in human skin. Most
importantly, a direct correlation was observed between plasma-modiﬁed permeation data and literature data
through calculation of membrane permeability (Kp) values suggesting plasma-modiﬁed silicone membrane
(PMSM) could be considered as a suitable in vivo replacement to predict clinical skin permeation.
1. Introduction
Poly(dimethylsiloxane), also known as PDMS, is a commonly used
polymer based on its favourable properties including transparency, gas
permeability and generally high level of stability [1]. The basic
structure of the polymer is composed of –O–Si(CH3)2– units which
can be manufactured according to a variety of speciﬁc requirements
depending upon the constraints of the application, i.e. several types are
available with speciﬁc functions [2]. The extensive range of uses of
PDMS includes air separation [3,4], environmental control [5], separa-
tion of liquid mixtures [6], wound dressings and medical applications
[7,8], microﬂuidics [9–11] and biochemical sensing [12]. As a result of
such a diverse and extensive breadth of functionalities, a substantial
amount of literature can be found on the properties of PDMS (see
previous references), such as the dependence of gas permeability on
membrane thickness (thus requiring reliable preparation techniques)
[13].
As expected, researchers have attempted to modify the surface of
PDMS to enhance its suitability, particularly in the ﬁeld of micro-
ﬂuidics. This is because biological samples easily and strongly interact
with PDMS surfaces because of the inherent hydrophobicity of the
material which has led to numerous applications of modiﬁed PDMS
surfaces in biological assays, such as biomolecule separation, immu-
noassay [14], cell culture and DNA hybridisation [15].
One particularly interesting modiﬁcation to standard PDMS that
has been the subject of investigation in recent years is modiﬁcation of
the surface using plasma treatment. It is generally accepted that PDMS
(upon exposure to plasma) develops silanol groups (–OH) at the
expense of methyl groups (–CH3) [16,17] as a result of oxidation of
the surface layer [18]. This creates a more highly hydrophilic surface
which can be observed through a reduction in the contact angle of
water [19] and may cause a wrinkling eﬀect under certain conditions
[20]. As a consequence of this transformation, the properties of the
membrane are transformed. For example, it has been reported that
freshly oxidised PDMS showed a signiﬁcantly smaller gas diﬀusion
coeﬃcient compared with untreated membrane [21]. In some studies
the process of plasma surface treatment is the ﬁrst step in a series of
procedures to modify the surface, i.e. to create a variety of more
complex products that have diﬀerent properties to the original PDMS
or to avoid certain disadvantages. For example, following plasma
treatment it is possible to immerse the membrane in acrylic acid, then
immobilise with chitosan and gelatin and ﬁnally culture ﬁbroblast cells
onto the surface to enhance cell growth [22]. Other compounds have
also been incorporated onto the surface of plasma-treated PDMS, for
example self-assembled amphipathic ﬁlm, to address nonspeciﬁc
protein adsorption issues, thus broadening the potential uses of
PDMS-based microﬂuidic chips in complex biological analysis [23].
There is one area of analytical research that utilises PDMS, yet has
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not previously considered plasma-treated surface modiﬁcation, namely
the use of PDMS to determine the permeation of pharmaceutical
compounds for the prediction of skin permeability [24]. Traditionally,
such permeation studies utilise human or, more frequently, animal skin
whereby the amount of a compound is monitored over a period of time
as it permeates across the skin layer from a donor to receiver phase
[25]. This data is essential for a large variety of chemicals where there
is the likelihood they will, at some point, come into contact with human
skin, such as cosmetics, pharmaceuticals and household products. In
recent years PDMS has been proposed as an ethical, economic and
reliable alternative for the determination of compound permeation
along with several other techniques [26]. For example, when permea-
tion of diﬀerent vehicles was considered, a trend between ﬂux values
for the model membrane and skin was evident, suggesting that silicone
membrane may provide information on qualitative trends [27]. This is
particularly useful for compounds intended for use in cosmetic
products, where the use of animal testing within the EU and several
other countries is no longer an option. However, it has been found that
the data generated does not always directly relate to in vivo data and
can be aﬀected by a variety of factors, such as the presence of
surfactants [28,29]. In the current work we consider the impact on
permeation for a set of model compounds following transformation of
the hydrophobic surface of PDMS using plasma surface treatment with
the intention to create a more hydrophilic (i.e. more skin-like [30]),
and therefore potentially more suitable in vitro model.
2. Experimental
2.1. Plasma surface treatment method
Polydimethylsiloxane (PDMS) sheets (Silatos™) were used as
purchased from ATOS, Sweden (150 mm × 200 mm × 0.13 mm).
Disks were cut with a diameter of 14 mm and placed in a benchtop
laboratory plasma unit (Henniker Scientiﬁc) under low pressure on full
power (40 kHz, 100 W). This was then repeated on the alternate
surface under identical conditions with both surfaces exposed for
90 s each (based on the knowledge that a more prolonged exposure
time can result in cracking [31]). Contact angle analysis and permea-
tion studies were performed immediately (within one hour) after
plasma treatment to avoid storage stability issues. To examine the
stability of the plasma-treated PDMS membrane, permeation analysis
of a model compound (lidocaine) was performed through freshly
treated and aged membrane. Results showed the membrane retained
its hydrophilic surface even after eight weeks of storage (data not
shown), suggesting stability was not an issue in this study.
Furthermore, polar solvents, such as those used in this study, are
known to enhance the stability of plasma-treated membranes, thus
ensuring stability is not an issue in this work.
2.2. Contact angle analysis
The static contact angle of the untreated and treated PDMS samples
was measured by the sessile drop method using an optical goniometer
with attached precision syringe (FTA1000, Surface Science
Instruments, USA). A drop of deionised water was dispensed from
the syringe onto the freshly treated PDMS surface below. A minimum
of three measurements were taken for each sample from diﬀerent
locations on the surface to determine an average value.
2.3. Permeation studies
Sixteen model compounds were analysed using a Franz-type,
bespoke, diﬀusion cell system with a diﬀusional area of 0.64 cm2:
aminopyrine (Fisher Scientiﬁc, Loughborough, UK, ≥ 97%), benzoic
acid (Sigma Aldrich, Dorset, UK, ≥ 99.5%), caﬀeine (Sigma Aldrich,
Dorset, UK, ≥ 99%), ethyl 4-hydroxybenzoate (Sigma Aldrich, Dorset,
UK, ≥ 99%), ethyl 4-aminobenzoate (Sigma Aldrich, Dorset, UK, >
98%), ibuprofen (BASF, ≥ 99%), lidocaine (Sigma Aldrich, Dorset, UK,
≥ 98%), methyl 4-hydroxybenzoate (Sigma Aldrich, Dorset, UK, ≥
98%), methyl 4-aminobenzoate (Sigma Aldrich, Dorset, UK, ≥ 98%),
propyl 4-hydroxybenzoate (Sigma Aldrich, Dorset, UK, ≥ 99%), propyl
4-aminobenzoate (Alfa Aesar, Lancashire, UK, 98%), ﬂurbiprofen
(Tokyo Chemical Industry Ltd, > 98%), diclofenac (Tokyo Chemical
Industry Ltd, > 98%), ketoprofen (Tokyo Chemicals Industry Ltd, >
98%), acetyl salicylic acid (Sigma Aldrich, Dorset, UK, ≥ 99%) and
salicylic acid (Sigma Aldrich, Dorset, UK, ≥ 99.5%), all as saturated
solutions placed in the donor phase. In all cases samples were analysed
using a UV spectrophotometer (Agilent Technologies, UK) to determine
concentrations at a suitable wavelength for each drug.
Donor and receiver phases consisted of sonicated 0.05 M pH 7.4
phosphate buﬀered saline (K2HPO4, Sigma Aldrich, Dorset, UK,
KH2PO4, Sigma Aldrich, Dorset, UK and NaCl, Fisher Scientiﬁc Ltd.,
Loughborough, UK) and an experimental temperature of 32 °C. Cells
were stirred and left to equilibrate for 30 min, i.e. the equilibration
period receptor phase remained as the starting experimental receptor
phase solution. 0.6 mL samples were extracted from the 1.5 mL
receptor phase every 45 min and replaced with fresh buﬀer for a total
of 6 h. Membrane permeability (Kp) values were then calculated using
all data points for all compounds from t=0 except in the case of caﬀeine
where an initial lag period of 60 min was discarded from calculation as
a result of the comparatively low extent of permeation. Upon addition
of compound to the donor phase the buﬀer was unable to maintain the
original pH and so the pH was measured for each resultant solution to
allow calculation of the distribution coeﬃcient (log D). Solubility data
required for analysis is presented in Table S1.
3. Results and discussion
3.1. Surface hydrophobicity
PDMS is renowned for its hydrophobic nature with typical static
water contact angle (WCA) measurements in the region of ≥ 100° [19].
Water contact angles were measured for PDMS as received and then
again after plasma treatment. Prior to treatment the average WCA was
found to be 112.3° ( ± 0.9) whereas after plasma treatment the contact
angle had reduced to an average of 60.7° ( ± 5.1). These results conﬁrm
that the plasma treatment process had signiﬁcantly reduced the
hydrophobicity of the surface, as expected based on previous literature
[32].
3.2. Permeation analysis
3.2.1. Eﬀect of surface treatment on permeation
As can be seen in Fig. 1, pre-treatment of the silicone membrane
used in the permeation analysis results in a signiﬁcant reduction in
cumulative amount permeated over a 6 h period for benzoic acid. This
conﬁrms that even though it is only the surface of the silicone that has
been modiﬁed through the plasma treatment, the eﬀect on the overall
properties of the membrane is signiﬁcant. This result presents the ﬁrst
reported evidence that plasma treatment on silicone membrane can
aﬀect the permeation of pharmaceutical compounds, which is an
important ﬁnding based on the fact that permeation studies are often
used when analysing pharmaceutical compounds.
Interestingly, across the range of compounds analysed, the degree
to which plasma treatment altered the permeability proﬁle varied
somewhat. As previously mentioned, the cumulative amount of benzoic
acid permeated was dramatically reduced by replacing standard
membrane with plasma treated membrane. This considerable eﬀect
was also observed for several other compounds, for example, ibupro-
fen, lidocaine and aminopyrine. In contrast, several compounds did not
exhibit a dramatic reduction in permeation using membrane pre-
treated with plasma, as exempliﬁed in Fig. 2 with caﬀeine. Other
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compounds for which permeation was not dramatically reduced by
replacement with plasma treated membrane included ethyl 4-amino-
benzoate and diclofenac.
As it was found experimentally that diﬀerent compounds resulted in
diﬀerent total amounts permeated, both with standard, unmodiﬁed
membrane and plasma treated membrane, the data was simpliﬁed to
allow a clearer interpretation to be made. This was achieved by
considering the total cumulative amount permeated using plasma-
treated membrane as a percentage of the total cumulative amount
permeated using standard, unmodiﬁed membrane. A summary of the
values (after a total experimental time of 6 h) can be seen in Table 1.
Based on the data in Table 1, it can be seen that the most signiﬁcant
reduction in permeation was generally observed for compounds with
the lower polar surface areas. These ﬁndings indicate that polarity
plays an important role in permeation, as is seen in biological systems
such as intestinal absorption [33], blood-brain barrier permeation [34]
and human skin permeation. Based on previous work, transdermal
penetration has been linked with structural predictors, such as polar
surface area whereby the usefulness of such parameters has been
assessed [35]. It would appear that our plasma-treated membrane
ﬁndings ﬁt well with published literature [36], as illustrated in Fig. 3,
and that treatment has an impact on the permeation of a set of
compounds to varying extents which can be linked to polar surface
area (R2=−0.73, values for PSA derived using Chemspider (www.
chemspider.com)).
Assuming that the surface of the membrane has a negative charge
overall, the more water soluble compounds (which may have a dipolar
eﬀect) were removed from the dataset and the linearity was recon-
sidered. It was found that there was no change in the linearity of the
data after the removal of the more hydrophilic compounds.
Furthermore, analysis was undertaken to consider if logD, molecular
weight or hydrogen bonding were related to the reduction in permea-
tion and no signiﬁcant relationship was observed (data not shown). In
addition, Table 1 shows that polar surface area is not directly related to
the amount permeated, either unmodiﬁed or plasma treated, conﬁrm-
ing it is the change in permeation that is related to polar surface area
rather than the speciﬁc permeation values.
3.2.2. Suitability of plasma-treated silicone to predict in vivo skin
membrane permeability
Kp is frequently considered when investigating the behaviour of
compounds through skin for inter-laboratory studies, although it
should be noted that maximum ﬂux is sometimes considered for
individual studies [37]. Skin permeability may be characterised by
Fig. 1. Cumulative amount permeated for benzoic acid using (▲) unmodiﬁed silicone
membrane and (■) plasma surface-treated silicone membrane (n=3, ±SD).
Fig. 2. Cumulative amount permeated for caﬀeine using (▲) unmodiﬁed silicone
membrane and (■) plasma surface-treated silicone membrane (n=3, ±SD).
Table 1
Total cumulative amount of compound permeated after 6 h through unmodiﬁed and plasma-treated membrane, also expressed as a percentage reduction (%). Polar surface area (PSA)
values were calculated using Chemspider (www.chemspider.com).
Compound Amount permeated
Unmodiﬁed membrane
(μg/cm2)
Plasma-treated membrane
(μg/cm2)
Reduction (%) PSA (Å2)
Acetyl salicylic acid 561.1 432.1 23.00 64
Aminopyrine 3360.5 1727.7 48.59 27
Benzoic acid 3507.5 1893.8 46.01 37
Caﬀeine 58.92 66.73 −13.27 58
Diclofenac 41.11 38.50 6.351 49
Ethyl 4-aminobenzoate 1519.56 1543.58 −1.581 52
Ethyl 4-hydroxybenzoate 782.8 631.8 19.29 47
Flurbiprofen 345.0 279.7 18.93 37
Ibuprofen 1916.6 868.0 54.71 37
Ketoprofen 118.1 96.03 18.93 54
Lidocaine 4911.4 2819.24 42.60 36
Methyl 4-aminobenzoate 2346.51 1760.04 24.99 52
Methyl 4-hydroxybenzoate 818.76 601.5 26.53 47
Propyl 4-aminobenzoate 1495.01 1473.85 1.415 52
Propyl 4-hydroxybenzoate 679.76 425.15 37.46 47
Salicylic acid 1841.8 1437.4 21.96 58
Butyl 4-aminobenzoate 901.1 714.1 20.75 52
Butyl 4-hydroxybenzoate 782.4 652.1 16.66 47
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both steady state ﬂux and permeability coeﬃcient, and whilst steady
state ﬂux appears more practical from a clinical perspective as it can be
used readily to evaluate the use of delivery devices, it does not allow for
the normalisation of concentration and therefore hinders inter-pene-
trant comparisons. Furthermore, signiﬁcant quantities of permeability
data have been published in the form of permeability coeﬃcients, for
example the large collection of skin permeability data published by
Flynn [38] which allows for comparative analysis such as this work to
be undertaken. Researchers have attempted to simplify the prediction
of Kp to aid the development of formulations using a variety of in vitro
systems (for example [39] and [40]), mainly with the aim of either
avoiding the use of animal testing or for economic reasons [26]. An
ideal skin mimic system will result in Kp values that correlate well with
literature. Permeability data acquired during this study is presented in
Table 2 for both standard PDMS membrane and plasma-treated
membrane for a set of compounds. These are presented along with
literature values [41–45] which were selected based on their similarity
to the experimental conditions used during this study.
Membrane permeability values using standard membrane (for
comparison) and then using plasma pre-treated membrane were
calculated and compared with literature data (Figs. 4 and 5). Using
standard PDMS membrane produced a partially linear relationship
between experimental and literature data (R2= 0.77). Although this will
allow some prediction of permeability, it cannot be considered a close
enough ﬁt to be conﬁdent in predicting data for compounds beyond
those considered in this study. However, if the PDMS membrane is ﬁrst
plasma treated and then used for analysis with the same set of
compounds, the linearity increases signiﬁcantly with an R2= 0.88.
This method oﬀers an improved system using plasma-treated mem-
brane for permeability analysis and would provide an enhanced
experimental in vitro system for predictive purposes.
Kp is constant for a particular compound and is a reﬂection of the
ability to cross the membrane, normalised by concentration. In an ideal
situation, a compound should always provide an identical value, regard-
less of vehicle formulation based on the assumption that the compound
does not interact with the formulation components. In this case, a slightly
diﬀerent scenario is presented in that diﬀerent Kp values were observed
for a compound with identical formulations yet diﬀerent membrane
Fig. 3. Reduction in the cumulative amount permeated using silicone membrane to
highlight the importance of polar surface area (PSA).
Table 2
Experimental membrane permeability (Kp) values (× 10
−4) for both standard PDMS
membrane and plasma-treated membrane, presented alongside literature permeability
data [41–45]. All results are expressed as the mean ± S.D. (n = 3).
Compound Membrane permeability (Kp) × 10
−4 (cm/min)
Standard PDMS Plasma-treated PDMS Literature
Acetyl salicylic acid 1.255 ± 0.051 0.9821 ± 0.0709 0.085 [41]
Aminopyrine 2.01 ± 0.11 1.075 ± 0.139 0.198 [42]
Benzoic Acid 11.38 ± 0.40 6.236 ± 0.428 2.94 [43]
Caﬀeine 0.08840 ± 0.00440 0.1026 ± 0.0120 0.108 [42]
Diclofenac 0.6099 ± 0.0316 0.5618 ± 0.0272 0.167 [44]
Ethyl 4-
aminobenzoate
47.83 ± 1.56 49.35 ± 0.98 12.1 [42]
Ethyl 4-
hydroxybenzoate
18.40 ± 0.47 15.00 ± 1.03 2.32 [42]
Flurbiprofen 2.169 ± 0.063 1.767 ± 0.126 0.379 [43]
Ibuprofen 11.91 ± 0.54 5.432 ± 0.514 0.56 [43]
Ketoprofen 0.3557 ± 0.0193 0.2944 ± 0.0126 1.17 [43]
Lidocaine 36.11 ± 1.54 22.98 ± 1.09 4.209 [45]
Methyl 4-
aminobenzoate
36.45 ± 2.54 27.80 ± 2.31 11.04 [42]
Methyl 4-
hydroxybenzoate
7.092 ± 0.363 5.698 ± 0.359 1.49 [42]
Propyl 4-
hydroxybenzoate
39.43 ± 0.62 26.17 ± 1.65 2.18 [42]
Propyl 4-
aminobenzoate
55.04 ± 1.75 55.31 ± 2.27 13.4 [42]
Salicylic Acid 6.560 ± 0.359 5.158 ± 0.142 2.30 [44]
Butyl 4-
aminobenzoate
109.9 ± 5.8 89.21 ± 7.61 12.1 [38]
Butyl 4-
hydroxybenzoate
71.21 ± 3.28 60.94 ± 3.91 16.62 [38]
Fig. 4. Relationship between experimental Kp values (standard membrane) and
literature Kp values (R
2 = 0.77).
Fig. 5. Relationship between experimental Kp values (plasma-treated membrane) and
literature Kp values (R
2= 0.88).
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properties. This ﬁnding implies there must be an interaction between the
membrane itself and the compound to result in the diﬀerence in Kp values
observed for the majority of the compounds analysed.
4. Conclusions
In summary, this study presents the ﬁrst attempt to modify PDMS
membrane using plasma treatment to determine the subsequent eﬀect
on permeability analysis. It can be seen that it is possible to modify the
permeability of compounds through the membrane and the extent of
the eﬀect is dependent upon the polar surface area of the permeating
molecule. Furthermore, plasma-treated membrane is a more suitable
system for the in vitro analysis of compounds as it has been found to
correlate more closely with literature data compared with standard
PDMS membrane.
5. Summary
Predicting the permeation of compounds through skin is currently
one of the biggest obstacles in replacing the use of animals in
pharmaceutical analysis. Although PDMS has shown some promise
as a skin mimic, the results did not match literature data closely
enough for it to be deemed a suitable alternative. This paper considers
modiﬁcation of the membrane using plasma treatment which was then
tested with a set of compounds and found to closely match literature
data from established in vivo systems. Thus, proving that modiﬁed
PDMS is a suitable skin mimic for the pharmaceutical industry to adopt
to replace current systems.
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